pmc-enju-pas Home  

PMC:3359311 / 0-383 JSONTXT 12 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T89 0-21 JJ denotes Inflammasome-Mediated
T90 22-27 NN denotes IL-1β
T91 28-38 NN denotes Production
T92 39-41 IN denotes in
T93 42-48 NN denotes Humans
T94 49-53 IN denotes with
T95 54-60 JJ denotes Cystic
T96 61-69 NN denotes Fibrosis
T97 117-127 NN denotes Background
T98 128-140 NN denotes Inflammation
T99 141-144 CC denotes and
T100 145-154 NN denotes infection
T101 155-158 VB denotes are
T102 159-164 JJ denotes major
T103 165-177 NN denotes determinants
T104 178-180 IN denotes of
T105 181-188 NN denotes disease
T106 189-197 NN denotes severity
T107 198-201 CC denotes and
T108 202-214 RB denotes consequently
T109 214-215 -COMMA- denotes ,
T110 216-219 DT denotes the
T111 220-227 NN denotes quality
T112 228-230 IN denotes of
T113 231-235 NN denotes life
T114 236-239 CC denotes and
T115 240-247 NN denotes outcome
T116 248-251 IN denotes for
T117 252-260 NN denotes patients
T118 261-265 IN denotes with
T119 266-272 JJ denotes cystic
T120 273-281 NN denotes fibrosis
T121 282-283 -LRB- denotes (
T122 283-285 NN denotes CF
T123 285-286 -RRB- denotes )
T124 288-301 NN denotes Interleukin-1
T125 302-306 NN denotes beta
T126 307-308 -LRB- denotes (
T127 308-313 NN denotes IL-1β
T128 313-314 -RRB- denotes )
T129 315-317 VB denotes is
T130 318-319 DT denotes a
T131 320-323 JJ denotes key
T132 324-336 JJ denotes inflammatory
T133 337-345 NN denotes mediator
T134 347-356 NN denotes Secretion
T135 357-359 IN denotes of
T136 360-372 RB denotes biologically
T137 373-379 JJ denotes active
R45 T91 T89 arg1Of Production,Inflammasome-Mediated
R46 T91 T90 arg1Of Production,IL-1β
R47 T91 T92 arg1Of Production,in
R48 T93 T92 arg2Of Humans,in
R49 T93 T94 arg1Of Humans,with
R50 T96 T94 arg2Of Fibrosis,with
R51 T96 T95 arg1Of Fibrosis,Cystic
R52 T98 T99 arg1Of Inflammation,and
R53 T99 T101 arg1Of and,are
R54 T100 T99 arg2Of infection,and
R55 T103 T101 arg2Of determinants,are
R56 T103 T102 arg1Of determinants,major
R57 T103 T104 arg1Of determinants,of
R58 T103 T108 arg1Of determinants,consequently
R59 T103 T109 arg1Of determinants,","
R60 T104 T107 arg1Of of,and
R61 T106 T104 arg2Of severity,of
R62 T106 T105 arg1Of severity,disease
R63 T108 T107 arg2Of consequently,and
R64 T111 T109 arg2Of quality,","
R65 T111 T110 arg1Of quality,the
R66 T111 T112 arg1Of quality,of
R67 T111 T116 arg1Of quality,for
R68 T113 T114 arg1Of life,and
R69 T114 T112 arg2Of and,of
R70 T115 T114 arg2Of outcome,and
R71 T117 T116 arg2Of patients,for
R72 T117 T118 arg1Of patients,with
R73 T120 T118 arg2Of fibrosis,with
R74 T120 T119 arg1Of fibrosis,cystic
R75 T120 T121 arg1Of fibrosis,(
R76 T122 T121 arg2Of CF,(
R77 T123 T121 arg3Of ),(
R78 T125 T124 arg1Of beta,Interleukin-1
R79 T125 T126 arg1Of beta,(
R80 T125 T129 arg1Of beta,is
R81 T127 T126 arg2Of IL-1β,(
R82 T128 T126 arg3Of ),(
R83 T133 T129 arg2Of mediator,is
R84 T133 T130 arg1Of mediator,a
R85 T133 T131 arg1Of mediator,key
R86 T133 T132 arg1Of mediator,inflammatory
R87 T134 T135 arg1Of Secretion,of
R89 T137 T136 arg1Of active,biologically